KLK3 and prostate adenocarcinoma: The patient was initially diagnosed in 2012 with Gleason 7, prostate-specific antigen (PSA) 13.72 ng/mL, and cT2aN0M0 prostate adenocarcinoma and was treated with external beam radiation therapy to 7770 cGy in 42 fractions to the prostate fossa and six months of androgen deprivation therapy (ADT).